Correlation Between Dupont De and Inhibikase Therapeutics
Can any of the company-specific risk be diversified away by investing in both Dupont De and Inhibikase Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Dupont De and Inhibikase Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Dupont De Nemours and Inhibikase Therapeutics, you can compare the effects of market volatilities on Dupont De and Inhibikase Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Dupont De with a short position of Inhibikase Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Dupont De and Inhibikase Therapeutics.
Diversification Opportunities for Dupont De and Inhibikase Therapeutics
-0.52 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between Dupont and Inhibikase is -0.52. Overlapping area represents the amount of risk that can be diversified away by holding Dupont De Nemours and Inhibikase Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibikase Therapeutics and Dupont De is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Dupont De Nemours are associated (or correlated) with Inhibikase Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibikase Therapeutics has no effect on the direction of Dupont De i.e., Dupont De and Inhibikase Therapeutics go up and down completely randomly.
Pair Corralation between Dupont De and Inhibikase Therapeutics
Allowing for the 90-day total investment horizon Dupont De Nemours is expected to generate 0.28 times more return on investment than Inhibikase Therapeutics. However, Dupont De Nemours is 3.57 times less risky than Inhibikase Therapeutics. It trades about 0.04 of its potential returns per unit of risk. Inhibikase Therapeutics is currently generating about -0.18 per unit of risk. If you would invest 7,685 in Dupont De Nemours on October 20, 2024 and sell it today you would earn a total of 62.00 from holding Dupont De Nemours or generate 0.81% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Dupont De Nemours vs. Inhibikase Therapeutics
Performance |
| Timeline |
| Dupont De Nemours |
| Inhibikase Therapeutics |
Dupont De and Inhibikase Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Dupont De and Inhibikase Therapeutics
The main advantage of trading using opposite Dupont De and Inhibikase Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Dupont De position performs unexpectedly, Inhibikase Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibikase Therapeutics will offset losses from the drop in Inhibikase Therapeutics' long position.| Dupont De vs. Eastman Chemical | Dupont De vs. Olin Corporation | Dupont De vs. Cabot | Dupont De vs. Kronos Worldwide |
| Inhibikase Therapeutics vs. DiaMedica Therapeutics | Inhibikase Therapeutics vs. Milestone Pharmaceuticals | Inhibikase Therapeutics vs. Seres Therapeutics | Inhibikase Therapeutics vs. Oncolytics Biotech |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Complementary Tools
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |